Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17671177
Ma L, et al. (2007) Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res 67, 7106-12 17671177
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, colorectal cancer, endometrial cancer, kidney cancer, tuberous sclerosis
Relevant cell lines - cell types - tissues:  'brain, cerebral cortex', breast cell-breast, colon, endometrium, kidney, MDA-MB-231 (breast cell), NCI-H1650 (pulmonary), SK-MEL2 (melanocyte)
Cellular systems studied:  cell lines, tissue
Species studied:  human
Comments:  SK-MEL28 cells (not SK-MEL2 cells)
Associated Diseases
Diseases Alterations Comments
tuberous sclerosis increased

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, colorectal cancer, endometrial cancer, kidney cancer, tuberous sclerosis
Relevant cell lines - cell types - tissues:  'brain, cerebral cortex', breast cell-breast, colon, endometrium, kidney, MDA-MB-231 (breast cell), NCI-H1650 (pulmonary), SK-MEL2 (melanocyte)
Cellular systems studied:  cell lines, tissue
Species studied:  human
Comments:  SK-MEL28 cells (not SK-MEL2 cells)
Associated Diseases
Diseases Alterations Comments
tuberous sclerosis increased

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, colorectal cancer, endometrial cancer, kidney cancer, tuberous sclerosis
Relevant cell lines - cell types - tissues:  'brain, cerebral cortex', breast cell-breast, colon, endometrium, kidney, MDA-MB-231 (breast cell), NCI-H1650 (pulmonary), SK-MEL2 (melanocyte)
Cellular systems studied:  cell lines, tissue
Species studied:  human
Comments:  SK-MEL28 cells (not SK-MEL2 cells)
Associated Diseases
Diseases Alterations Comments
tuberous sclerosis increased

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, colorectal cancer, endometrial cancer, kidney cancer, tuberous sclerosis
Relevant cell lines - cell types - tissues:  'brain, cerebral cortex', breast cell-breast, colon, endometrium, kidney, MDA-MB-231 (breast cell), NCI-H1650 (pulmonary), SK-MEL2 (melanocyte)
Cellular systems studied:  cell lines, tissue
Species studied:  human
Comments:  SK-MEL28 cells (not SK-MEL2 cells)
Associated Diseases
Diseases Alterations Comments
tuberous sclerosis increased

S240-p - S6 (human)
Modsite: RLssLRAstsKsEss SwissProt Entrez-Gene
Orthologous residues
S6 (human): S240‑p, S6 (mouse): S240‑p, S6 (rat): S240‑p, S6 (fruit fly): S239‑p, S6 (cow): S240‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  colorectal cancer, colorectal carcinoma, kidney cancer, tuberous sclerosis
Relevant cell lines - cell types - tissues:  'brain, cerebral cortex', colon, kidney
Cellular systems studied:  tissue
Species studied:  human
Associated Diseases
Diseases Alterations Comments
tuberous sclerosis increased

S244-p - S6 (human)
Modsite: LRAstsKsEssQK__ SwissProt Entrez-Gene
Orthologous residues
S6 (human): S244‑p, S6 (mouse): S244‑p, S6 (rat): S244‑p, S6 (fruit fly): V243‑p, S6 (cow): S244‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Disease tissue studied:  colorectal cancer, colorectal carcinoma, kidney cancer, tuberous sclerosis
Relevant cell lines - cell types - tissues:  'brain, cerebral cortex', colon, kidney
Cellular systems studied:  tissue
Species studied:  human
Associated Diseases
Diseases Alterations Comments
tuberous sclerosis increased

S664-p - TSC2 (human)
Modsite: KkTSGPLsPPTGPPG SwissProt Entrez-Gene
Orthologous residues
TSC2 (human): S664‑p, TSC2 iso2 (human): S664‑p, TSC2 iso3 (human): S664‑p, TSC2 iso4 (human): S664‑p, TSC2 (mouse): S664‑p, TSC2 iso6 (mouse): S664‑p, TSC2 (rat): S664‑p, TSC2 iso2 (rat): S664‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, colorectal cancer, endometrial cancer, kidney cancer, tuberous sclerosis
Relevant cell lines - cell types - tissues:  'brain, cerebral cortex', breast cell-breast, colon, endometrium, HEK293T (epithelial), kidney, MDA-MB-231 (breast cell), NCI-H1650 (pulmonary), SK-MEL2 (melanocyte)
Cellular systems studied:  cell lines, tissue
Species studied:  human
Comments:  SK-MEL28 cells (not SK-MEL2 cells)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme, phospho-antibody
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme, phospho-antibody
Comments:  MEK-DD is constitutively active upstream enzyme.
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
U0126 phorbol_ester inhibit treatment-induced increase
Associated Diseases
Diseases Alterations Comments
tuberous sclerosis increased